Thiazolidinediones: effects on insulin resistance and the cardiovascular system.

Medicine and Dentistry

• Maturity Onset Diabetes of the Young 100%
• Therapeutic Procedure 100%
• Cardiovascular Risk 100%
• Cardiovascular System 100%
• Insulin Resistance 100%
• Peroxisome Proliferator Activated Receptor Gamma 100%
• Adipose Tissue 100%
• Development 50%
• Inpatient 50%
• Interleukin 6 50%
• Intima-Media Thickness 50%
• Cardiovascular System 50%
• Receptor 50%
• Tumor Necrosis Factor 50%
• Adiponectin 50%
• Peroxisome Proliferator Activated Receptor Alpha 50%
• Atherosclerosis 50%
• Hyperglycemia 50%
• Inflammatory Mediator 50%
• Plasminogen Activator Inhibitor-1 50%
• Heart Protection 50%
• Insulin Sensitivity 50%
• Rosiglitazone 50%
• Fatty Acid Transport 50%

Pharmacology, Toxicology and Pharmaceutical Science

• Cardiovascular Risk 100%
• Non Insulin Dependent Diabetes Mellitus 100%
• Insulin Resistance 100%
• Peroxisome Proliferator Activated Receptor Gamma 100%
• Insulin 50%
• Atherosclerosis 50%
• Receptor 50%
• Tumor Necrosis Factor 50%
• Peroxisome Proliferator Activated Receptor Alpha 50%
• Fatty Acid 50%
• Hyperglycemia 50%
• Interleukin 6 50%
• Plasminogen Activator Inhibitor 1 50%
• Adiponectin 50%
• Rosiglitazone 50%